KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $59.4 million.

  • Amneal Pharmaceuticals' Cash from Financing Activities rose 16436.99% to $59.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.6 million, marking a year-over-year increase of 6714.09%. This contributed to the annual value of -$211.8 million for FY2024, which is 36.79% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $59.4 million for Q3 2025, which was up 16436.99% from -$41.7 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Cash from Financing Activities peaked at $59.4 million during Q3 2025, and registered a low of -$100.8 million during Q4 2023.
  • Moreover, its 5-year median value for Cash from Financing Activities was -$38.1 million (2021), whereas its average is -$36.3 million.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Cash from Financing Activities tumbled by 35487.44% in 2023 and then skyrocketed by 16436.99% in 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$30.4 million in 2021, then rose by 26.96% to -$22.2 million in 2022, then tumbled by 354.87% to -$100.8 million in 2023, then soared by 39.3% to -$61.2 million in 2024, then soared by 197.12% to $59.4 million in 2025.
  • Its Cash from Financing Activities was $59.4 million in Q3 2025, compared to -$41.7 million in Q2 2025 and -$39.2 million in Q1 2025.